New England Journal of Medicine· 2019Q1
Relaps veya Refrakter FLT3 Mutasyonlu AML İçin Gilteritinib veya Kemoterapi
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
- 1.254atıf
- Q1SCImago
- 2019yıl
Kısa özet
Gilteritinib, relaps veya refrakter FLT3 mutasyonlu AML hastalarında kurtarma kemoterapisine kıyasla genel sağkalımı (9.3 aya karşı 5.6 ay) ve tam remisyon oranlarını (%34.0'e karşı %15.3) anlamlı şekilde iyileştirmiştir.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- Gilteritinib, kurtarma kemoterapisine kıyasla ortalama genel sağkalımı 9.3 aya (KB 5.6 ay) uzatmıştır (HR 0.64, P<0.001).
- Gilteritinib grubunda hastaların %34.0'ü hematolojik iyileşmeyle birlikte tam remisyona ulaşırken, kemoterapi grubunda bu oran %15.3'tür (risk farkı %18.6).
- Ortalama olaydan sağkalım gilteritinib grubunda 2.8 ay, kemoterapi grubunda ise 0.7 ay olmuştur.
- Gilteritinib grubunda derece 3 ve üzeri yan etkiler daha az sıklıkta görülmüştür; yaygın yan etkiler arasında ateşli nötropeni (%45.9), anemi (%40.7) ve trombositopeni (%22.8) bulunmaktadır.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
BACKGROUND: -mutated AML. METHODS: -mutated AML in a 2:1 ratio to receive either gilteritinib (at a dose of 120 mg per day) or salvage chemotherapy. The two primary end points were overall survival and the percentage of patients who had complete remission with full or partial hematologic recovery. Secondary end points included event-free survival (freedom from treatment failure [i.e., relapse or lack of remission] or death) and the percentage of patients who had complete remission. RESULTS: Of 371 eligible patients, 247 were randomly assigned to the gilteritinib group and 124 to the salvage chemotherapy group. The median overall survival in the gilteritinib group was significantly longer than that in the chemotherapy group (9.3 months vs. 5.6 months; hazard ratio for death, 0.64; 95% confidence interval [CI], 0.49 to 0.83; P<0.001). The median event-free survival was 2.8 months in the gilteritinib group and 0.7 months in the chemotherapy group (hazard ratio for treatment failure or death, 0.79; 95% CI, 0.58 to 1.09). The percentage of patients who had complete remission with full or partial hematologic recovery was 34.0% in the gilteritinib group and 15.3% in the chemotherapy group (risk difference, 18.6 percentage points; 95% CI, 9.8 to 27.4); the percentages with complete remission were 21.1% and 10.5%, respectively (risk difference, 10.6 percentage points; 95% CI, 2.8 to 18.4). In an analysis that was adjusted for therapy duration, adverse events of grade 3 or higher and serious adverse events occurred less frequently in the gilteritinib group than in the chemotherapy group; the most common adverse events of grade 3 or higher in the gilteritinib group were febrile neutropenia (45.9%), anemia (40.7%), and thrombocytopenia (22.8%). CONCLUSIONS: -mutated AML. (Funded by Astellas Pharma; ADMIRAL ClinicalTrials.gov number, NCT02421939.).
Yazarların özeti; kaynağından alınmıştır. New England Journal of Medicine, 2019 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
Alan: Hematoloji
HematologyMedicine